Y-mAbs Therapeutics

Biotech & Life Sciences · New York City, United States · Founded 2014 · IPO 2018

Y-mAbs Therapeutics was founded in 2015 by Thomas Gad, with a mission to develop innovative cancer treatments. The company focuses on creating antibody-based therapies, particularly targeting pediatric oncology. In its early years, Y-mAbs concentrated on developing a robust pipeline of drug candidates. Their dedication to addressing unmet medical needs in cancer treatment quickly garnered attention in the biotech community. A significant milestone for Y-mAbs came in September 2018, when the company went public on the NASDAQ under the ticker YMAB. The IPO was a pivotal moment, providing the necessary capital to advance their clinical trials and expand their research capabilities. Y-mAbs has since made notable progress, particularly with its lead product candidates, which have shown promise in treating neuroblastoma, a rare pediatric cancer. The company's commitment to innovation and patient care continues to drive its research and development efforts. Today, Y-mAbs stands as a testament to the impact of focused scientific research and the potential of antibody-based therapies in transforming cancer treatment. The journey of Y-mAbs Therapeutics highlights the importance of perseverance and innovation in the biopharmaceutical industry.

Valuation $332M

Revenue $88M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Investors

3 investors on Y-mAbs Therapeutics's cap table

Sourced from Dealroom's funding history.

Series B+ 3 investors entered at this stage

Sofinnova Investments

Scopia Capital

Memorial Sloan - Kettering Cancer Center

Global footprint

Where Y-mAbs Therapeutics has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States59.3%

🇩🇰 Denmark40.7%

2 countries shown

Web traffic by country

4.9K monthly visits
across markets

🇺🇸 United States65.3%

🇮🇳 India24.5%

🇯🇵 Japan10.2%

Top 3 markets shown

Talent graph

The shape of Y-mAbs Therapeutics's talent

Dealroom maps Y-mAbs Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 team members profilednamed & role-tagged by Dealroom

57 employeestotal headcount

4 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Y-mAbs Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$378k patent portfolio · 6 active families

Estimated portfolio value

$378k

0.11% of market cap · 186.5× smaller than top peer Bioarctic ($71M)

6 active patent families

Where Y-mAbs Therapeutics innovates AntibodyAntigenAntigen Binding FragmentCD33Carcinosis

Where Y-mAbs Therapeutics concentrates vs peers

Each axis is a top-10 topic across Y-mAbs Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Y-mAbs Therapeutics

An AI-synthesized read of the highest-engagement posts about Y-mAbs Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Y-mAbs Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles